When will PN-477 be available? This is one of the most common questions among those following this breakthrough triple-agonist peptide. As a next-gen therapy for obesity, PN-477 is still in early development, but here’s what we know so far about the release timeline and when you might be able to access it.
Current Status
As of mid-2025, PN-477 is in the preclinical phase. Protagonist Therapeutics officially announced the compound as a development candidate on June 30, 2025. That marked the end of discovery research and the start of toxicology and formulation work required for human testing.
No version of PN-477 is currently approved for sale or use in any country.
Estimated Clinical Trial & Approval Timeline
- Q1 2026: IND (Investigational New Drug) application submitted to FDA
- Q2 2026: Phase 1 clinical trials begin
- Late 2026–2027: Phase 2 trials in obese and diabetic patients
- 2028: Phase 3 multicenter trials begin
- Late 2028 to 2029: NDA filing and potential FDA approval
Based on this progression, the earliest availability of PN-477 would likely be 2029—depending on trial success and regulatory strategy.
Will It Be Available Earlier for Research or Compassionate Use?
Some patients wonder if they can access PN-477 before formal approval through special programs. Here are a few possible—but rare—early access routes:
- Clinical Trial Participation: Enrolling in Phase 2 or 3 trials may allow access
- Expanded Access/Compassionate Use: Possible for severe obesity or diabetes if no alternatives exist (unlikely before 2028)
- Research-Only Supply: It is illegal to distribute PN-477 for self-experimentation before FDA approval
The only legitimate way to access PN-477 before commercial launch will be by joining a clinical trial.
Where Will PN-477 Be Available First?
Like most innovative therapies, PN-477 will likely launch in the United States first, followed by Europe and other major markets. Country-by-country availability depends on how quickly local regulatory agencies approve the compound after U.S. trials conclude.
Expected Launch Regions:
- 🇺🇸 USA – likely first (FDA approval)
- 🇪🇺 EU – Germany, France, Netherlands via EMA
- 🇨🇦 Canada – subject to Health Canada review
- 🇦🇺 Australia – potential late-stage rollout
The UK (NHS) may offer limited access at first, depending on cost-effectiveness compared to Wegovy and Mounjaro.
Oral vs Injectable Availability
PN-477 is unique in being developed in both injectable and oral forms. The injectable (PN-477sc) is likely to enter trials first, with the oral version (PN-477o) following shortly after.
Expected order of availability:
- PN-477sc (injection) — first to complete trials
- PN-477o (oral tablet) — dependent on absorption/formulation success
If the oral form works well, it could become the preferred option among patients, but regulatory agencies may treat them as separate approvals.
Will It Be Available Online or in Clinics?
Once approved, PN-477 will likely be distributed through:
- Licensed pharmacies (retail and mail-order)
- Telehealth weight loss providers (e.g., Ro, Calibrate, Found)
- Endocrinology and bariatric clinics
Online "research peptide" vendors offering PN-477 prior to approval should be avoided—they are not legal or safe sources.
Stay Notified
As development progresses, this page will be updated with:
- Clinical trial announcements
- Regulatory approvals
- Retail availability by country
Join our Discord to get notified first:
Summary
PN-477 is expected to reach patients by 2029 if all goes well in trials. Until then, your best option is to monitor its progress, sign up for trial alerts, and stay informed through reputable sources.
Bookmark this site and check back often for the latest updates on PN-477 availability worldwide.